Precision Medicine in Oncology
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Special Reports in Personalized Cancer Care
SELECT A TOPIC
Attend An Event
State of the Science Summit
Regional Seminar Series
Giants of Cancer Care
Precision Medicine in Oncology
<< View More Conferences
2018 ASCO Annual Meeting
Oncology Conference Multimedia
View more videos >>
Dr. Gupta on Impact of Pembrolizumab Plus Bevacizumab Findings in RCC
Dr. Tewari on the Promise of Immunotherapy in Cervical Cancer
Dr. Abramson Discusses Lisocabtagene Maraleucel in NHL
Oncology Conference Articles
Frontline Atezolizumab Regimen Improves Survival for NSCLC
The combination of atezolizumab, bevacizumab, carboplatin, and paclitaxel educed the risk of death by 22% compared with bevacizumab and chemotherapy in patients with advanced wild-type non-squamous non–small cell lung cancer.
Chemoprevention Reduces Risk for Esophageal Cancer
A combination of 2 over-the-counter medicines can moderately reduce the risk for high-grade dysplasia or esophageal cancer in patients with Barrett’s esophagus if taken for at least 7 years.
NKTR-214/Nivolumab Efficacy Sustained in Phase II Findings
Combining the CD122-biased cytokine NKTR-214 with the PD-1 inhibitor nivolumab (Opdivo) showed promising antitumor activity, particularly in PD-L1–negative patients.
Pancreatic Cancer Survival Jumps With Postsurgical Chemo Combo
A 4-drug chemotherapy combination dramatically improved survival compared with standard gemcitabine as postoperative therapy for patients with resected pancreatic cancer.
Cemiplimab Reaches Near 50% Response in Metastatic CSCC
The PD-1 inhibitor cemiplimab induced an overall response rate of 47.5% in patients with metastatic cutaneous squamous cell carcinoma.
Neoadjuvant Chemoradiotherapy May Improve OS Over Adjuvant Standard-of-Care in Pancreatic Cancer
Preoperative treatment with chemotherapy and radiation improved overall survival rates for patients with resectable or borderline resectable pancreatic cancer compared with immediate surgery.
Heated Chemo During Resection Shows No Benefit in Advanced CRC
The addition of heated chemotherapy delivered to the abdomen during surgery delivered no survival benefit to patients with peritoneal carcinomatosis.
Liso-Cel Shows Durable CRs for High-Risk DLBCL
Lisocabtagene maraleucel (JCAR017; liso-cel) demonstrated a durable complete remission rate of 46% at 6 months for patients with high-risk diffuse large B-cell lymphoma.
CD22 Immunotoxin Achieves Durable Complete Remissions in Relapsed Hairy Cell Leukemia
Moxetumomab pasudotox, a first-in-class recombinant immunotoxin targeting CD22, produced deep and durable responses in a substantial proportion of pretreated patients with relapsed/refractory hairy cell leukemia.
Rituximab/Lenalidomide Potential Frontline Therapy for Follicular Lymphoma
Similar efficacy with the combination of rituximab and lenalidomide coupled with a better safety profile compared with rituximab plus chemotherapy may make the chemo-free regimen a new frontline option for patients with previously untreated follicular lymphoma.
Anti-CD47 Antibody Plus Rituximab Demonstrates Efficacy in Half of Patients With Relapsed/Refractory NHL
Half of a small group of patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL) had major responses to treatment with an anti-CD47 antibody plus rituximab (Rituxan).
Pegilodecakin Plus PD-1 Inhibitor Shows Potential in NSCLC
Combining pegilodecakin with nivolumab or pembrolizumab induced an overall response rate of 41% in patients with advanced non–small cell lung cancer.
Frontline Ibrutinib/Venetoclax Combo Shows High MRD-Negative Responses for CLL
The frontline combination of ibrutinib and venetoclax demonstrated a 100% objective response rate for patients with chronic lymphocytic leukemia, with 77% of patients testing negative for minimal residual disease in the peripheral blood after 6 cycles.
Erdafitinib Active in Advanced Metastatic Urothelial Carcinoma
More than 40% of patients with metastatic or unresectable urothelial carcinoma responded to treatment with an investigational fibroblast growth factor receptor inhibitor.
Early OS Data Support Phase III Trial With AKT Inhibitor Ipatasertib for TNBC
First-line treatment with the oral AKT inhibitor ipatasertib shows a promising trend toward improving overall survival when added to paclitaxel for the treatment of locally advanced or metastatic triple-negative breast cancer.
Ribociclib Prolongs PFS With Fulvestrant in First- or Second-Line HR-Positive, HER2-Negative Advanced Breast Cancer
Adding the CDK4/6 inhibitor ribociclib to fulvestrant significantly prolonged progression-free survival in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who received no or 1 prior line of therapy.
Lenvatinib-Pembrolizumab Combo Has Promising Activity in Squamous Cell Head and Neck Cancer
Lenvatinib added to pembrolizumab demonstrated promising activity in patients with squamous cell carcinoma of the head and neck in an ongoing open-label phase Ib/II clinical trial.
Pembrolizumab Plus Chemo Emerges as New Standard in Frontline Squamous NSCLC
Adding pembrolizumab to frontline carboplatin/paclitaxel or nab-paclitaxel reduced the risk of death by 36% compared with chemotherapy alone in patients with metastatic squamous non–small cell lung cancer.
Endocrine Therapy Alone Is Sufficient in HR+/HER2- Breast Cancer With Intermediate Recurrence Score
Adjuvant endocrine therapy alone is noninferior to adjuvant chemoendocrine therapy in patients with hormone receptor–positive, HER2-negative, node-negative early-stage breast cancer.
Sunitinib Noninferior to Surgery for OS in Metastatic Kidney Cancer
Sunitinib alone was noninferior to cytoreductive nephrectomy plus sunitinib, the current standard of care, in patients with synchronous metastatic renal cell carcinoma.
Maintenance Therapy Changes Paradigm in Rare Childhood Sarcoma
A course of low-dose maintenance chemotherapy administered after standard-of-care intensive chemotherapy led to significant improvements in disease-free and overall survival in pediatric rhabdomyosarcoma.
Frontline Pembrolizumab Bests Chemo in NSCLC, Especially in PD-L1-High Subgroup
Patients with non-small cell lung cancer treated with frontline pembrolizuma lived 4 to 8 months longer than those who received standard of care chemotherapy.
Matched Targeted Therapy Extends Survival in Advanced Hard-to-Treat Cancers
Personalized therapy based on tumor molecular profiling resulted in improved overall survival for patients with advanced, hard-to-treat cancers.
cfDNA Assays Demonstrate High Specificity for Early Stage Lung Cancer Detection
Initial results from the Circulating Cell-Free Genome Atlas study strongly suggest that cell-free DNA tests can be used with a high degree of specificity to detect signs of early stage lung cancer.
Pembrolizumab Studies Show Disparate Data on Link Between AE and Response in Multiple Myeloma
Pembrolizumab (Keytruda) yielded inconsistent results regarding the relationship between immune-related adverse events and objective response in multiple myeloma.
Microsatellite Instability Status Links to Lynch Syndrome in Broad Array of Cancers
Microsatellite instability-high tumors are more likely to be associated with the presence of Lynch syndrome. Yet, 45% of patients with cancers not typically identified with Lynch syndrome actually qualify for germline genetic testing.
Only Modest Benefit Seen With Taselisib in PIK3CA-Mutant Breast Cancer
Treatment with taselisib in combination with fulvestrant provided a modest progression-free survival benefit of 2 months compared with fulvestrant alone in patients with estrogen receptor–positive,
-mutant locally advanced or metastatic breast cancer
Once Weekly Carfilzomib Superior in Relapsed/Refractory Myeloma
Carfilzomib (Kyprolis) administered once weekly at 70 mg/m
with dexamethasone resulted in a prolonged PFS compared with the standard twice-weekly schedule in patients with relapsed/refractory multiple myeloma.
Atezolizumab Plus Chemo Extends PFS in Frontline Squamous NSCLC
The addition of atezolizumab (Tecentriq) to frontline carboplatin and nab-paclitaxel (Abraxane) delayed the risk of progression or death by 29% compared with chemotherapy alone for patients with advanced squamous NSCLC.
LOXO-292 Shows Impressive Response Rates for RET-Positive Tumors
The highly-selective RET inhibitor LOXO-292 demonstrated robust clinical activity across RET-altered solid tumors, including in patients with brain metastases and the
V804M gatekeeper mutation.
Ibrutinib/Rituximab Reduces Progression Risk by 80% in Waldenstrom Macroglobulinemia
Adding ibrutinib to rituximab lowered the risk of disease progression or death by 80% versus rituximab alone in patients with Waldenström macroglobulinemia.
bb2121 Adds Nearly 1 Year of PFS for Heavily Pretreated Myeloma
bb2121 had a median progression-free survival of 11.8 months and a median duration of response of 10.8 months for patients with relapsed/refractory heavily pretreated multiple myeloma.
Pomalidomide Triplet Extends PFS in Relapsed/Refractory Myeloma
Adding pomalidomide (Pomalyst) to bortezomib (Velcade) and low-dose dexamethasone reduced the risk of disease progression or death by 39% in patients with relapsed/refractory multiple myeloma with prior exposure to lenalidomide.
Venetoclax/Carfilzomib Combo Highly Effective for t(11;14) Myeloma
The addition of venetoclax to carfilzomib and dexamethasone demonstrated a 100% objective response rate with a very good partial response or better rate of 86% for patients with relapsed/refractory t(11;14) multiple myeloma.
Colorectal Cancer Treatment Twice as Costly in US Than Canada, Despite Similar Outcomes
A study that compared costs of treatment for metastatic colorectal cancer in Western Washington and the province of British Columbia in Canada found that prices were more than twice as high for the US patients than for their Canadian counterparts, with no significant difference in outcomes.
Geriatric Assessment Improves Patient Satisfaction, Patient-Oncologist Communication
Evaluating health-related concerns as part of routine care for elderly patients with advanced cancer significantly improved doctor-patient communication and patient satisfaction.
Black Men May Fare Better Than White Men With Standard mCRPC Therapy
Black men with metastatic castration-resistant prostate cancer may experience greater benefits from chemotherapy and hormone-targeting treatment than their white counterparts.
Compared With Men, Women With Head and Neck Cancer Undertreated
Women with head and neck cancer may be severely undertreated and have higher death rates compared with their male counterparts.
ASCO 2018: Top Oncologists Select Key, Practice-Changing Abstracts
Key opinion leaders spoke with
ahead of the 2018 ASCO Annual Meeting to share the top abstracts they believe could have the greatest impact on clinical practice and patient outcomes across lymphomas, gastrointestinal cancers, genitourinary cancers, and lung cancer.
NGS Established as Most Cost-Effective Genetic Test for Metastatic NSCLC
Next-generation sequencing in metastatic non-small cell lung cancer can save Center for Medicare and Medicaid Services payers $1.4 million to $2.1 million.
Symptom Tracking System Reduces Severity in Patients With Head and Neck Cancer
Patients who used mobile and sensor technology to track their symptoms demonstrated reduced severity of their symptoms compared with patients who received standard care.
Despite USPSTF Recommendations and Medicaid Coverage, Data Show Low Lung Cancer Screening Rate
A total 1.9% of more than 7.6 million current and former heavy smokers in the United States underwent lung cancer screening in 2016, suggesting that it remains inadequate despite USPTF recommendations.
Shorter Trastuzumab Duration Matches 12-Month Standard for Early HER2+ Breast Cancer
A shorter 6-month course of adjuvant trastuzumab (Herceptin) was found to be noninferior for disease-free survival compared with the standard 12-month schedule for patients with HER2-positive early breast cancer.
Nelarabine Boosts 4-Year DFS Above 90% in Pediatric/AYA T-Cell Cancers
Adding nelarabine to escalating-dose methotrexate induced a 4-year disease-free survival rate of 91% in a cohort of pediatric and young adult patients with newly diagnosed T-cell cancers.
Cognitive Behavior Therapy, Acupuncture Improve Insomnia Symptoms in Cancer Survivors
Both cognitive behavior therapy for insomnia (CBT-I) and acupuncture produced clinically meaningful improvements in insomnia severity scores for cancer survivors, but data from the randomized CHOICE clinical trial showed that CBT-I was more effective overall for reducing the severity of insomnia.
OncLive News Network On Location: ASH 2019 Day 1
Liso-Cel Induces High Rate of Durable Responses in LBCL
Ibrutinib May Thwart PFS Decline In R/R Mantle Cell Lymphoma
Anti-BCMA CAR-T JNJ-4528 Hits 100% Response Rate in Heavily Pretreated Myeloma
Ibrutinib/Rituximab Combo Retains PFS Advantage Over FCR in Extended Follow-up
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2019
Intellisphere, LLC. All Rights Reserved.